The growing threat of antibiotic resistant bacterial and fungal pathogens requires new paradigms for addressing the worldwide threat of “superbugs.” These infectious agents have adapted to acquire resistance, in some cases, to all known antibiotics, opening up the real possibility of devastating epidemics.
Multi-drug resistant (MDR) pathogens represent an immediate danger to individuals and populations. Engineered Orynotides are highly effective in killing MDR bacteria in the test tube and in animal models. Moreover, sequential passage of these pathogens in Orynotide preparations fails to select for resistance to these novel peptide drugs.